The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically-relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were presented to the entire panel and a consensus was reached. This consensus, which was further developed in continuous post-meeting discussions, formed the basis of three manuscripts, each covering one of the three key areas identified. This manuscript presents the consensus recommendations regarding the clinical management of elderly patients diagnosed with malignant lymphoma. Four clinically-relevant topics identified by the panel were: 1) how to define patient fitness, 2) assessing quality of life, 3) diagnostic work-up and 4) clinical management of elderly patients with lymphoma. Each of these key topics is addressed in the context of five different lymphoma entities, namely: CLL, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript.
Antecedentes: Los síntomas depresivos, fatiga y apatía son síntomas comunes en los adultos mayores con enfermedades médicas y los pacientes con enfermedad avanzada, y se han asociado con una morbilidad y mortalidad. El metilfenidato se ha utilizado para tratar estos síntomas, debido a su efecto rápido. A pesar de la larga historia de uso de metilfenidato para el tratamiento de los síntomas depresivos, fatiga y apatía, hay poca evidencia definitiva que apoye su uso.
OBJETIVO: El objetivo de este trabajo fue revisar la eficacia y tolerabilidad del metilfenidato en el tratamiento de los síntomas depresivos, fatiga y apatía en los adultos mayores con enfermedades médicas y los adultos que reciben cuidados paliativos.
MÉTODOS: Inglés-artículos en el idioma que presentan las revisiones sistemáticas, ensayos clínicos, o series de casos que describe el uso de metilfenidato para el tratamiento de los síntomas depresivos, fatiga o apatía en adultos con enfermedades médicas de esa edad o adultos que reciben cuidados paliativos fueron identificados. El metilfenidato palabras clave y depresivo o bien, la depresión, la fatiga, la apatía o se utiliza para buscar en la base de datos Cochrane, MEDLINE, PsycINFO, e International Pharmaceutical Abstracts. Los artículos incluidos abordaron los síntomas de depresión, la fatiga, la apatía o en el (1) adultos mayores (por lo general, la edad mayor o igual a 65 años), particularmente aquellos con enfermedades graves concomitantes, (2) adultos que reciben cuidados paliativos, y (3) adultos con otras enfermedades crónicas enfermedades. Me excluyeron los artículos sobre el tratamiento de la depresión en adultos jóvenes sanos, el trastorno bipolar y el trastorno por déficit de atención y la narcolepsia, el síndrome de fatiga crónica y trastornos relacionados.
RESULTADOS: Un total de 19 ensayos controlados de metilfenidato en adultos con enfermedades médicas mayores de esa edad o los pacientes en cuidados paliativos fueron identificados. Desafortunadamente, sus resultados contradictorios, el reducido tamaño de la muestra, y de mala calidad metodológica limitada la capacidad para hacer inferencias respecto a la eficacia del metilfenidato, aunque la evidencia de la tolerancia era más fuerte. La evidencia disponible sugiere la posible eficacia del metilfenidato para los síntomas depresivos, fatiga y apatía en varias poblaciones de pacientes con enfermedades médicas.
CONCLUSIÓN: En la ausencia de pruebas definitivas de la eficacia, los ensayos de dosis bajas de metilfenidato en adultos enfermos que padecen de depresión, fatiga, o la apatía, con la supervisión de la respuesta y los efectos adversos, son las adecuadas.
PURPOSE: Cancer-related fatigue contributes to negative outcomes relative to psychosocial and symptom distress, functional status, and quality of life, and yet it is often underdiagnosed and management is frequently suboptimal. DESIGN: Systematic database searches were conducted, and primary research reports and meta-analyses of quantitative studies of interventions for fatigue published in English were identified and critically examined. RESULTS: This paper reviews the etiology and evaluation of cancer-related fatigue and analyzes current empirical evidence supporting pharmacologic and nonpharmacologic techniques for its management. DISCUSSION: A variety of pharmacologic and nonpharmacologic techniques to manage cancer-related fatigue have been studied, although most of the evidence is from single-arm pilot studies with small sample sizes, rather than from adequately powered, multicenter, randomized controlled trials. Continued research in ethnically and racially diverse samples is needed to identify the interventions that are most effective in specific cancer subpopulations and to develop and test interventions for fatigue at each phase in the illness trajectory.
The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically-relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were presented to the entire panel and a consensus was reached. This consensus, which was further developed in continuous post-meeting discussions, formed the basis of three manuscripts, each covering one of the three key areas identified. This manuscript presents the consensus recommendations regarding the clinical management of elderly patients diagnosed with malignant lymphoma. Four clinically-relevant topics identified by the panel were: 1) how to define patient fitness, 2) assessing quality of life, 3) diagnostic work-up and 4) clinical management of elderly patients with lymphoma. Each of these key topics is addressed in the context of five different lymphoma entities, namely: CLL, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript.
